Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.

Epigenomics - 1 Jul 2021

Bouchla Anthi, Thomopoulos Thomas P, Papageorgiou Sotirios G, Apostolopoulou Christina, Loucari Constantinos, Mpazani Efthimia, Pappa Vasiliki

Abstract excerpt

5-Azacitidine (5-AZA) is widely used for the treatment of higher-risk myelodysplastic syndromes. However, response and survival rates vary considerably, while indicated treatment duration remains undefined. For these reasons, factors determining response and survival are of major importance. Clinical, morphological, flow cytometry, cytogenetic and molecular factors are discussed in this review. Biomarkers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Biomarkers

Share to Disease Management

Share to Disease Susceptibility

Share to Myelodysplastic Syndromes

Share to Treatment Outcome

Source

Identifiers

PMID: 34291653
DOI: 10.2217/epi-2021-0124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.PMID 34291653Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

How I treat higher-risk MDSSemantic proximity Read ↗

Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.Semantic proximity Read ↗

How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments.Semantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Current therapeutic approaches for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.Semantic proximity Read ↗

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Semantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

[Hypomethylating agents for the treatment of myelodysplastic syndromes].Semantic proximity Read ↗

Survival of myelodysplastic syndrome patients after azacitidine therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.